Percutaneous Treatment of Tricuspid Valve Regurgitation With the TriCinch System™
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 24
- 试验地点
- 25
- 主要终点
- Safety: The percentage of participants with Major Adverse Events within 30 days of the procedure.
研究概览
简要总结
The TriCinch System™ is intended for percutaneous treatment of tricuspid regurgitation.
It is a percutaneous catheter-based device designed for tricuspid valve repair in order to decrease effective cross-sectional area and relieve symptoms in patients with tricuspid valve regurgitation.
详细描述
Implantation Procedure: Unlike the standard open chest, arrested heart approach, the 4TECH TriCinch System™ provides a percutaneous solution for tricuspid valve regurgitation treatment: this procedure is performed through deep sedation, while the heart is beating, without the need for respiratory assistance.
The TriCinch System™ consists of a Delivery System that enables transcatheter placement of an implant that can be adjusted to correct Tricuspid valve regurgitation. The TriCinch Delivery System is inserted from the femoral vein to access the right atrium of the heart. At the end of the correction process, the TriCinch Delivery System and the venous introducer are removed and the procedure is concluded.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Functional symptomatic tricuspid regurgitation (TR) 2+ to 4+ on a scale of 4+ (moderate to severe), with annular dilatation greater than 40mm.
- •Signed informed consent form prior to any study-related procedure.
- •Available and able to return to the study site for post-procedural follow-up examination
- •Eighteen (18) years of age or older.
排除标准
- •Requirement for concomitant cardiac procedure (other than atrial fibrillation correction surgery, closure of PFO (Patent Foramen Ovale) or ASD (Atrial Septal Defect), or PTCA (percutaneous treatment of coronary artery) or CAD (coronary artery bypass surgery) from 1 to 3 months after or before other procedure.
- •Presence of any known life threatening (non-cardiac major or progressive disease), non-cardiac disease that will limit the subject's life expectancy to less than one year.
- •Cerebro-vascular event within the past 6 months.
- •History of mitral/tricuspid endocarditis within the last 12 months.
- •Organic tricuspid disease.
- •Contraindication or known allergy to device's components, aspirin, anti-coagulation therapy or contrast media that cannot be adequately premeditated.
- •Severe hypertension (SBP ≥ 180 mmHg and/or DBP ≥ 110 mmHg, measurement done by sphygmomanometer with stethoscope, allow the patient to sit for at least 5 minutes before beginning BP measurements).
- •Female patient is pregnant (urine HCG test result positive) or lactating.
- •Known alcohol or drug abuser.
- •Currently participating in the study of an investigational drug or device.
- •At heart team's judgement, patient IVC dimension is not adequate for device implantation.
结局指标
主要结局
Safety: The percentage of participants with Major Adverse Events within 30 days of the procedure.
时间窗: Up to 30 days
Freedom from major adverse event: death, Q-wave myocardial infarction, cardiac tamponade, cardiac surgery for failed TriCinch implantation, stroke, or septicaemia.
Performance: The reduction in degree of tricuspid regurgitation measured immediately after the procedure compared to baseline.
时间窗: intraoperative
Ability to reduce tricuspid regurgitation by at least 1 degree immediately following implantation of the TriCinch device assessed by means of quantitative echocardiographic parameters.
Performance: The reduction in the degree of tricuspid regurgitation measured at time of discharge compared to baseline.
时间窗: Time of discharge - 5 days
Ability to reduce tricuspid regurgitation by at least 1 degree immediately following implantation of the TriCinch device assessed by means of quantitative echocardiographic parameters.
次要结局
- Performance: Assessment in the degree of Tricuspid Regurgitation at 6 months compared to baseline.(6 months)
- Safety: The percentage of participants with Major Adverse Events within 6 months of the procedure.(6 months)
- Safety: The percentage of participants with Major Adverse Events up to 3 months of the procedure.(3 months)
- Performance: Assessment in the degree of Tricuspid Regurgitation at 3 months compared to baseline.(3 months)